• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Gamida Cell Ltd. (Amendment)

    2/9/24 9:03:02 AM ET
    $GMDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GMDA alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 GAMIDA CELL LTD COMMON STOCK Cusip #M47364100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #M47364100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 9,375,628 Item 6: 0 Item 7: 9,408,902 Item 8: 0 Item 9: 9,408,902 Item 11: 7.021% Item 12: HC Cusip #M47364100 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 9,408,902 Item 8: 0 Item 9: 9,408,902 Item 11: 7.021% Item 12: IN Item 1(a). Name of Issuer: GAMIDA CELL LTD Item 1(b). Address of Issuer's Principal Executive Offices: 5 NAHUM HAFZADI STREET JERUSALEM, 95484 ISRAEL Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: M47364100 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 9,408,902 (b) Percent of Class: 7.021% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 9,408,902 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of GAMIDA CELL LTD. No one other person's interest in the COMMON STOCK of GAMIDA CELL LTD is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC * IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of GAMIDA CELL LTD at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $GMDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMDA

    DatePrice TargetRatingAnalyst
    11/16/2021$14.00 → $12.00Buy
    Needham
    11/16/2021$17.00 → $15.00Outperform
    Oppenheimer
    11/1/2021$11.00Buy
    Alliance Global Partners
    More analyst ratings

    $GMDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

      Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr

      7/22/24 8:30:00 AM ET
      $ARVN
      $GMDA
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • XORTX Welcomes New Member to the Board of Directors

      CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors. Abigail "Abbey" L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ:GMDA) and a member of its Board of Directors. Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry deliv

      4/8/24 7:30:00 AM ET
      $GMDA
      $XRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

      WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p

      4/1/24 8:00:00 AM ET
      $AQST
      $EBS
      $GMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $GMDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Gamida Cell Ltd. (Amendment)

      SC 13G/A - Gamida Cell Ltd. (0001600847) (Subject)

      4/1/24 5:49:42 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Gamida Cell Ltd. (Amendment)

      SC 13G/A - Gamida Cell Ltd. (0001600847) (Subject)

      2/14/24 2:14:47 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Gamida Cell Ltd. (Amendment)

      SC 13G/A - Gamida Cell Ltd. (0001600847) (Subject)

      2/14/24 2:08:53 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Moch Kenneth I was granted 200,000 units of Ordinary Shares, increasing direct ownership by 619% to 232,300 units (SEC Form 4)

      4 - Gamida Cell Ltd. (0001600847) (Issuer)

      2/2/24 4:55:12 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wills Stephen T was granted 200,000 units of Ordinary Shares, increasing direct ownership by 356% to 256,177 units (SEC Form 4)

      4 - Gamida Cell Ltd. (0001600847) (Issuer)

      2/2/24 4:48:32 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tomasello Shawn was granted 200,000 units of Ordinary Shares, increasing direct ownership by 476% to 241,977 units (SEC Form 4)

      4 - Gamida Cell Ltd. (0001600847) (Issuer)

      2/2/24 4:45:46 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

      For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p

      4/17/23 1:02:15 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    Financials

    Live finance-specific insights

    See more

    $GMDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $GMDA
    SEC Filings

    See more
    • Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results

      BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 and provide an update on the company on Wednesday, March 27, 2024. Following the release, management will host a conference call and live webcast at 8:30 AM Eastern Time to discuss the financial results and provide a business update. Conference Call Dial-In & Webcast Information: Date/Time:Wednesday, March 27, 2024 at 8:30 AM Eastern TimeDomestic:1-877-425-9470International:1-201-389-0878Conference ID:13744446Call

      3/22/24 8:00:00 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gamida Cell to Report Third Quarter 2023 Financial Results

      BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the third quarter ended September 30, 2023 and provide an update on the company on Tuesday, November 14, 2023. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide business updates and answer questions. Conference Call Dial-In & Webcast Information:  Date/Time:Tuesday, November 14, 2023 at 8:30 AM Eastern Time Domestic:1-877-425-9470 International:1-201-389-0878 Conference ID:13741

      11/1/23 8:00:00 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gamida Cell to Report Second Quarter 2023 Financial Results

      Conference Call and Webcast Scheduled for Monday, August 14th at 8:30 am Eastern Time Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the second quarter ended June 30, 2023 on Monday, August 14, 2023. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates and answer questions. To access the conference call by phone, please register here and be advised to do so at least 10 minutes prior to joining. A live webcast of the conference call can be accessed b

      8/1/23 8:00:00 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Needham reiterated coverage on Gamida Cell with a new price target

      Needham reiterated coverage of Gamida Cell with a rating of Buy and set a new price target of $12.00 from $14.00 previously

      11/16/21 9:17:28 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer reiterated coverage on Gamida Cell with a new price target

      Oppenheimer reiterated coverage of Gamida Cell with a rating of Outperform and set a new price target of $15.00 from $17.00 previously

      11/16/21 8:13:09 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alliance Global Partners initiated coverage on Gamida Cell with a new price target

      Alliance Global Partners initiated coverage of Gamida Cell with a rating of Buy and set a new price target of $11.00

      11/1/21 9:03:50 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Gamida Cell Ltd.

      EFFECT - Gamida Cell Ltd. (0001600847) (Filer)

      5/14/24 12:15:25 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Gamida Cell Ltd.

      EFFECT - Gamida Cell Ltd. (0001600847) (Filer)

      5/14/24 12:15:20 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Gamida Cell Ltd.

      EFFECT - Gamida Cell Ltd. (0001600847) (Filer)

      5/14/24 12:15:14 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    Leadership Updates

    Live Leadership Updates

    See more
    • HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

      Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr

      7/22/24 8:30:00 AM ET
      $ARVN
      $GMDA
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • XORTX Welcomes New Member to the Board of Directors

      CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors. Abigail "Abbey" L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ:GMDA) and a member of its Board of Directors. Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry deliv

      4/8/24 7:30:00 AM ET
      $GMDA
      $XRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

      WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p

      4/1/24 8:00:00 AM ET
      $AQST
      $EBS
      $GMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)